Prostate Ca treatment increases diabetes risk
ANDROGEN deprivation therapy (ADT) may raise the risk of diabetes in men who have had prostate cancer, according to the findings of a study presented at the Endocrine Society’s 93rd Annual Meeting in Boston.
Researchers in the Philippines compared 38 men who had received ADT with 36 men who had less advanced prostate cancer and did not receive hormonal therapy. Apart from average age, other risk factors for diabetes had been similar between the two groups at the beginning of the study.
However, when researchers later reviewed medical records they found men who had been treated with ADT had twice the risk of type 2 diabetes (42% of the ADT group developed diabetes compared with 19% of the other group).